课题基金 / 基金详情

DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB

DIRECT ADMIN /ADENOVIRIDAE VECTOR W/VEGF121/ CDNA TO LOWER ISCHEMIC LIMB
直接管理/腺病毒载体 W/VEGF121/ CDNA 至下肢缺血
批准号：
6263933
负责人：
RONALD G CRYSTAL
金额：
$7.95万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6263933
关键词：
Adenoviridae blood disorder chemotherapy blood vessel occlusion blood vessels clinical research clinical trials drug administration routes gene therapy human subject human therapy evaluation ischemia limbs transfection /expression vector vascular endothelial growth factors

项目摘要

项目成果

RONALD G CRYSTAL的其他基金

相关文献

中文摘要
翻译
该方案旨在确定将AdGVVEGF 121.10载体直接施用至患有外周血管疾病的个体的下肢的安全性/毒性和生物学功效。 在研究结束时，除了上述目的之外，研究者将证明直接向下肢施用AdGVVEGF 121.10是否会诱导侧支血管的生长，并改善缺血区域的血流。
英文摘要
This protocol is designed to determine the safety/toxicity and biologic efficacy of direct administration of the AdGVVEGF121.10 vector to the lower limb of individuals with peripheral vascular disease. At the conclusion of the study, in addition to the objective described above, the investigators will demonstrate whether direct administration of AdGVVEGF121.10 to the lower limb will induce growth of collateral blood vessels, and improve blood flow in the region of ischemia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Ancillary SOURCE Study: Characterization of Small Airway Basal Cell Biology in Early COPD
Anti-eosinophil Gene Therapy for Eosinophilic Esophagitis
  • 批准号：
    10481279
  • 项目类别：
  • 资助金额：
    $30.0万
  • 财政年份：
    2022
  • 负责人：
    RONALD G CRYSTAL
  • 依托单位：
    ENYX THERAPEUTICS, LLC
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia
Phase IA/IB Study of AAVrh.10hFXN Therapy to Treat the Cardiomyopathy of Friedreich's Ataxia